Spero Therapeutics Files 8-K on Financials
Ticker: SPRO · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Spero Therapeutics dropped an 8-K on March 27th detailing their financials. Check it for the latest.
AI Summary
On March 27, 2025, Spero Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on Spero Therapeutics' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial data or material events that would indicate a high or medium risk.
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- March 27, 2025 (date) — Date of Report
- 001-38266 (other) — Commission File Number
- 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Spero Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Spero Therapeutics, Inc.'s results of operations and financial condition, as well as to provide financial statements and exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on March 27, 2025.
What is Spero Therapeutics, Inc.'s state of incorporation?
Spero Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Spero Therapeutics, Inc.?
The Commission File Number for Spero Therapeutics, Inc. is 001-38266.
Where are Spero Therapeutics, Inc.'s principal executive offices located?
Spero Therapeutics, Inc.'s principal executive offices are located at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding Spero Therapeutics, Inc. (SPRO).